X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (131) 131
hiv infections - drug therapy (111) 111
female (105) 105
male (105) 105
adult (102) 102
index medicus (100) 100
infectious diseases (100) 100
middle aged (77) 77
immunology (63) 63
anti-hiv agents - therapeutic use (58) 58
hiv infections - virology (55) 55
treatment outcome (55) 55
hiv (53) 53
tenofovir (51) 51
drug therapy (50) 50
antiretroviral therapy (47) 47
drug therapy, combination (46) 46
anti-hiv agents - administration & dosage (44) 44
viral load (43) 43
adenine - analogs & derivatives (41) 41
aids/hiv (40) 40
anti-hiv agents - adverse effects (40) 40
human immunodeficiency virus--hiv (40) 40
rna, viral - blood (40) 40
safety (39) 39
aged (38) 38
double-blind method (38) 38
virology (38) 38
hiv infection (36) 36
emtricitabine (35) 35
hiv-1 - drug effects (35) 35
antiretroviral drugs (34) 34
cd4 lymphocyte count (32) 32
dosage and administration (32) 32
young adult (32) 32
pharmacology & pharmacy (31) 31
lamivudine (30) 30
research (30) 30
hiv-1 (29) 29
antiviral agents (28) 28
efficacy (28) 28
therapy (28) 28
adenine - therapeutic use (27) 27
clinical trials (26) 26
drug administration schedule (26) 26
adenine - administration & dosage (25) 25
efavirenz (25) 25
double-blind (23) 23
hiv-1 - genetics (23) 23
adolescent (22) 22
deoxycytidine - analogs & derivatives (22) 22
drug combinations (22) 22
lamivudine - therapeutic use (22) 22
organophosphonates - administration & dosage (21) 21
ritonavir (21) 21
health aspects (20) 20
hiv infections - immunology (20) 20
lamivudine - administration & dosage (20) 20
microbiology (20) 20
abacavir (19) 19
abridged index medicus (19) 19
aids (19) 19
hiv-1 - isolation & purification (19) 19
protease inhibitors (19) 19
ritonavir - therapeutic use (19) 19
deoxycytidine - administration & dosage (18) 18
dideoxynucleosides - therapeutic use (18) 18
drug resistance, viral (18) 18
hiv/aids (18) 18
pharmacokinetics (18) 18
ritonavir - administration & dosage (18) 18
organophosphonates - therapeutic use (17) 17
adults (16) 16
atazanavir sulfate (16) 16
medicine, general & internal (16) 16
adenine - adverse effects (15) 15
care and treatment (15) 15
cobicistat (15) 15
dideoxynucleosides - administration & dosage (15) 15
raltegravir (15) 15
reverse transcriptase inhibitors - administration & dosage (15) 15
reverse transcriptase inhibitors - therapeutic use (15) 15
ribonucleic acid--rna (15) 15
viruses (15) 15
combination (14) 14
comparative analysis (14) 14
hiv infections - blood (14) 14
lamivudine - adverse effects (14) 14
rna (14) 14
antiretroviral therapy, highly active - methods (13) 13
deoxycytidine - therapeutic use (13) 13
infections (13) 13
analysis (12) 12
anti-hiv agents - pharmacology (12) 12
carbamates - administration & dosage (12) 12
hiv protease inhibitors - administration & dosage (12) 12
infection (12) 12
organophosphonates - adverse effects (12) 12
raltegravir potassium (12) 12
reverse transcriptase inhibitors - adverse effects (12) 12
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 10/2011, Volume 53, Issue 8, pp. 807 - 816
Background. We compared 3 years of antiretroviral therapy with raltegravir or efavirenz as part of a combination regimen in the ongoing STARTMRK study of... 
HIV/AIDS | Antiretrovirals | Fasting | HIV | Body fat | Response rates | Viruses | Lipids | Fats | Virology | HIV 1 | INFECTIOUS DISEASES | RESISTANT HIV-1 INFECTION | MULTICENTER | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | THERAPY | DOUBLE-BLIND | LOPINAVIR/RITONAVIR | SUBGROUP | Humans | Male | RNA, Viral - blood | Viral Load | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Adenine - adverse effects | HIV-1 - isolation & purification | Adult | Deoxycytidine - adverse effects | Female | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Absorptiometry, Photon | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Usage | Drug utilization | HIV patients | Dosage and administration | Drug therapy, Combination | Drug therapy | Efavirenz | Raltegravir
Journal Article
AIDS Research and Human Retroviruses, ISSN 0889-2229, 04/2018, Volume 34, Issue 4, pp. 337 - 342
Journal Article
Sexually Transmitted Infections, ISSN 1368-4973, 06/2017, Volume 93, Issue Suppl 1, p. A41
IntroductionAt Week(W) 48, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was statistically noninferior to E/C/F/tenofovir disoproxil... 
Journal Article
Journal Article
by Cahn, Pedro and Madero, Juan Sierra and Arribas, José Ramón and Antinori, Andrea and Ortiz, Roberto and Clarke, Amanda E and Hung, Chien-Ching and Rockstroh, Jürgen K and Girard, Pierre-Marie and Sievers, Jörg and Man, Choy and Currie, Alexander and Underwood, Mark and Tenorio, Allan R and Pappa, Keith and Wynne, Brian and Fettiplace, Anna and Gartland, Martin and Aboud, Michael and Smith, Kimberly and Cassetti, Lidia and David, Daniel and Figueras, Laura and Losso, Marcelo and Lopardo, Gustavo and Lupo, Sergio and Porteiro, Norma and Sánchez, Marisa and Bloch, Mark and Cooper, David and Finlayson, Robert and Kelleher, Anthony and Koh, Kenneth and Lewis, David and McMahon, James and Moore, Richard and Roth, Norman and Shields, Matthew and De Wit, Stephane and Florence, Eric and Goffard, Jean-Christophe and Demeester, Remy and Lacor, Patrick and Vandercam, Bernard and Vandekerckhove, Linos and Angel, Jonathan and Baril, Jean-Guy and Conway, Brian and De Pokomandy, Alexandra and Szabo, Jason and Walmsley, Sharon and Bouchaud, Olivier and Chidiac, Christian and Delobel, Pierre and Goujard, Cecile and Katlama, Christine and Molina, Jean-Michel and Pialoux, Gilles and Philibert, Patrick and Bogner, Johannes and Esser, Stefan and Krznaric, Ivanka and Lehmann, Clara and Spinner, Christoph and Stellbrink, Hans-Jurgen and Stephan, Christoph and Stoehr, Albrecht and Barchi, Enrico and Caramello, Pietro and Castelli, Francesco and Cattelan, Anna Maria and D'Arminio Monforte, Antonella and Di Biagio, Antonio and Di Perri, Giovanni and Gori, Andrea and Maggiolo, Franco and Menzaghi, Barbara and Migliorino, Guglielmo and Mussini, Cristina and Penco, Giovanni and Puoti, Massimo and Rizzardini, Giuliano and Gulminetti, Roberto and Lazzarin, Adriano and Quirino, Tiziano and Sighinolfi, Laura and Viale, Pierluigi and Amaya Tapia, Gerardo and Andrade Villanueva, Jaime and Granados Reyes, Enrique R and Perez Rios, Alma and Santoscoy Gomez, Mario and Den Hollander, Jan and Rijnders, Bart and Hidalgo, José A and Hercilla Vasquez, Luis and Illescas, Luis and Olczak, Anita and Mansinho, Kamal and Correia Pacheco, Patricia Paula and ... and GEMINI Study Team
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 143 - 155
Journal Article
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2016, Volume 3, Issue 4, pp. e158 - e165
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 08/2013, Volume 63, Issue 4, pp. 449 - 455
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2019
Abstract Background Doravirine (DOR) demonstrated noninferior efficacy to darunavir plus ritonavir (DRV+r) and efavirenz (EFV) in 2 ongoing phase 3 trials:... 
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2014, Volume 9, Issue 5, p. e96187
Simplification of antiretroviral therapy in patients with suppressed viremia may minimize long-term adverse effects. The study's primary objective was to... 
Anti-HIV Agents - pharmacology | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Male | Oligopeptides - adverse effects | Oligopeptides - therapeutic use | Lamivudine - adverse effects | Young Adult | Pyridines - adverse effects | Lipids - blood | Lamivudine - therapeutic use | Atazanavir Sulfate | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Pyridines - therapeutic use | HIV Infections - blood | Dideoxynucleosides - pharmacology | Anti-HIV Agents - adverse effects | Treatment Outcome | Biomarkers - blood | HIV Infections - drug therapy | Aged | Lamivudine - pharmacology | Pyridines - pharmacology | Oligopeptides - pharmacology | Viral Load - drug effects | Drug Combinations | Simplification | Viremia | Ritonavir | Coagulation | Clinical trials | Lipids | Tenofovir | Hepatitis | Randomization | Hyperbilirubinemia | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Quality | Human immunodeficiency virus--HIV | All terrain vehicles | Drug dosages | Lipoproteins (high density) | Emtricitabine | Antiretroviral drugs | Kidneys | Abnormalities | Lamivudine | Inflammation | Ribonucleic acid--RNA | Patients | Cholesterol | Antiretroviral therapy | Protease inhibitors | Abacavir | Biomarkers | Adults | Bone | Kidney transplantation | RNA | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 77 - 85
BACKGROUND:STARTMRK, a phase III noninferiority trial of raltegravir-based versus efavirenz-based therapy in treatment-naive patients, remained blinded until... 
raltegravir | HIV | STARTMRK | efavirenz | treatment naive | INFECTIOUS DISEASES | THERAPY | IMMUNOLOGY | HIV-1 INFECTION | SUBGROUP | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | HIV-1 | Oxazines | Humans | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Pyrrolidinones - therapeutic use | Benzoxazines - adverse effects | Treatment Outcome | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 4/2004, Volume 189, Issue 7, pp. 1185 - 1192
Journal Article